Patient handout

Cardiac tamponade — malignant pericardial effusion

PRODUCTION

1. Your condition

This handout is for cardiac tamponade — malignant pericardial effusion. Your care team identified this based on: known active malignancy (lung, breast, lymphoma, leukemia, melanoma, gi) presenting with new dyspnea + hypotension + jvd (lestuzzi heart 2010; ristić ehj 2014).

Other reasons your team may use this plan: echo: pericardial effusion (often large >2 cm) + rv diastolic collapse / ivc plethora in cancer patient (esc 2015 §neoplastic pericardial disease); incidental pericardial effusion on staging ct in oncology patient — outpatient triage to echo + tamponade screen (imazio jacc 2020 pmid 32919577); recurrent effusion within 30-90 days of prior pericardiocentesis in cancer patient → pericardial window indication (el haddad jacc 2015 pmid 26515995).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

Medication	Starting dose	How	When	What it does
normal saline	500-1000 mL bolus	IV	rapid bolus then reassess	Increase preload as bridge to drainage (ESC 2015)
norepinephrine	0.05-0.1 µg/kg/min titrate to MAP ≥65	IV	continuous	Bridge only — does not address obstruction (Roy JAMA 2007)
cisplatin	10-30 mg intrapericardial single dose post-drainage	intrapericardial	single dose; may repeat in 7d if persistent recurrence	Maisch ESC 2013 + Patel Eur J Cancer 2013 PMID 23290429 — durable response in lung ca; AVOID if eGFR <30; pre-medicate with antiemetics
bleomycin	15-60 mg intrapericardial	intrapericardial	single dose; may repeat	Lestuzzi Heart 2010 — alternative cytotoxic for non-lung primaries; pulmonary toxicity risk if systemic
mitomycin	5-10 mg intrapericardial	intrapericardial	single dose	Maisch ESC 2013 — third-line cytotoxic option for refractory recurrence

Plan: Malignant pericardial effusion — drainage with high-recurrence durability strategy (ESC 2015 §Neoplastic; Lestuzzi Heart 2010)

3. When to call your provider

Contact your care team if any of the following happen:

Recurrent tamponade → re-drainage + escalate to intrapericardial cytotoxic or repeat window per multidisciplinary review
Disease progression → systemic therapy intensification or hospice transition
Refractory symptoms → palliative care intensification

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

Re-accumulation within 30 days of initial pericardiocentesis in malignant etiology — predictor of >50% 90-day recurrence (El Haddad JACC 2015 PMID 26515995)
New bleeding into pericardial space post-cisplatin/bleomycin/mitomycin instillation OR baseline thrombocytopenia <30k → hemorrhagic effusion (Maisch ESC 2013)(life-threatening)
Acute LV dilation + LV dysfunction within 24h of large-volume (>1000 mL) pericardial drainage in chronic effusion (Pratt JACC 2019; reported in malignant effusions where chronic large effusions accumulate slowly)
Tamponade in patient with progressive metastatic cancer + ECOG ≥3 + life expectancy <3 mo — drainage decision is goals-of-care-driven (NCCN palliative 2024)
Neutropenic fever (ANC <500 + T ≥38.3) coinciding with malignant tamponade — purulent pericarditis must be excluded(life-threatening)

6. Sources

Guideline: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Neoplastic Pericardial Disease — remains current as of 2026-05-14. Lestuzzi Heart 2010 + Maisch ESC 2013 + NCCN palliative care 2024 anchor malignant-specific drainage durability + intrapericardial cytotoxic + multidisciplinary frameworks.